Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis

Launched by UNIVERSITY OF UTAH · Mar 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Transcranial Magnetic Stimulation (TMS) to see if it can help reduce depression in people with Multiple Sclerosis (MS). The researchers want to find out how safe and effective TMS is for those who have both MS and major depressive disorder, especially for those whose depression has not improved with other treatments. Participants in the study will receive TMS treatment for about 5 to 6 weeks while answering questionnaires and undergoing exams to track their progress.

To be eligible for this trial, individuals must have a confirmed diagnosis of MS and major depressive disorder. They should also be suitable candidates for TMS treatment. However, there are some exclusions, such as recent MS relapses, active thoughts of self-harm, or certain medical histories like seizures or bipolar disorder. The trial is currently looking for participants aged between 18 and 75, and anyone interested should discuss it with their healthcare provider to see if they qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Established diagnosis of multiple sclerosis (any subtype) by 2017 McDonald criteria
• • Established diagnosis of major depressive disorder (MDD) by DSM-5 criteria
• • Eligible for transcranial magnetic stimulation (rTMS) for depression
• Exclusion Criteria:
• • MS relapse and/or steroid use within 3 months
• • Active suicidal ideation
• • History of seizure/epilepsy, brain tumor, or stroke
• • History of bipolar disorder or psychosis
• • Currently or planning to become pregnant